In a patient with elevated hemoglobin/hematocrit, what red cell distribution width (RDW) values suggest polycythemia vera?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 8, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

RDW Values in Polycythemia Vera

In polycythemia vera (PV), red cell distribution width (RDW) is typically normal or only mildly elevated (generally ≤14–15%), in stark contrast to iron deficiency anemia where RDW is markedly elevated (>17–20%).

Understanding RDW in the Context of Elevated Hemoglobin/Hematocrit

Normal RDW Range and PV

  • The normal RDW reference range is approximately 13.0–14.0%, corresponding to the 95th percentile in healthy populations 1.
  • In untreated PV without iron deficiency, RDW remains normal or only minimally elevated because the clonal erythroid proliferation produces relatively uniform red cells 2.
  • When RDW is measured in PV patients, it may be slightly higher than normal controls when red blood cell counts are elevated, but this increase is modest compared to iron deficiency 2.

Iron Deficiency Complicating PV: The Key Diagnostic Pitfall

  • Iron deficiency frequently coexists with PV due to two mechanisms: (1) increased iron utilization by the proliferating erythroid compartment, and (2) repeated therapeutic phlebotomies that deplete iron stores 3.
  • When iron deficiency develops in PV, RDW becomes markedly elevated (>16–17%), reflecting the microcytic, hypochromic red cells mixed with residual normocytic cells from earlier production 4, 3.
  • A low mean corpuscular volume (MCV) with elevated RDW in a patient with borderline-high or even normal hemoglobin should trigger immediate suspicion for iron-deficient PV, as the iron deficiency can mask the true red cell mass elevation 4, 3.
  • The presence of microcytosis (low MCV) plus thrombocytosis, leukocytosis, splenomegaly, or aquagenic pruritus mandates JAK2 mutation testing regardless of hemoglobin level, because iron deficiency can suppress hemoglobin into the deceptively normal range 3.

Diagnostic Algorithm: Using RDW to Distinguish PV from Other Causes

Clinical Scenario Expected RDW Next Diagnostic Step Citation
Elevated Hb/Hct + normal RDW (≤14%) Suggests PV without iron deficiency Order JAK2 V617F mutation testing (detects >95% of PV) and serum erythropoietin (low in PV) [4]
Elevated Hb/Hct + mildly elevated RDW (14–16%) May represent early PV or secondary polycythemia Check serum ferritin, transferrin saturation, and JAK2 mutation; if JAK2 negative, evaluate for secondary causes (smoking, sleep apnea, EPO-producing tumors) [4,5]
Elevated Hb/Hct + markedly elevated RDW (>17%) Strongly suggests iron deficiency (either isolated IDA or iron-deficient PV) Measure serum ferritin and transferrin saturation; if iron deficient, perform JAK2 testing to exclude PV masked by iron deficiency [6,7]
Normal/borderline Hb + low MCV + elevated RDW (>16%) Iron deficiency masking PV Check for thrombocytosis, leukocytosis, splenomegaly; if present, order JAK2 mutation testing immediately [3]

Temporal Changes in RDW During PV Treatment

  • RDW in PV patients transiently increases following myelosuppressive therapy, corresponding to the transition period from microcytes (produced during iron-deficient states) to normal-sized red cells 2.
  • RDW is higher during the polycythemic phase than during the myelofibrotic phase of PV, reflecting active hematopoietic abnormality and extramedullary hematopoiesis 2.

Critical Pitfalls to Avoid

  • Do not exclude PV based solely on normal hemoglobin when RDW is elevated (>16%) and MCV is low (<80 fL), because iron deficiency can reduce the red cell mass to within normal reference ranges while the underlying clonal disorder persists 3.
  • Do not assume elevated RDW always indicates iron deficiency anemia alone; in the presence of thrombocytosis (platelets >450,000/μL), leukocytosis (WBC >12,000/μL), or splenomegaly, iron-deficient PV must be ruled out with JAK2 testing 4, 3.
  • RDW >17% strongly suggests iron deficiency (sensitivity 90% for IDA), but this can represent either isolated IDA or PV complicated by iron deficiency 6, 7.
  • RDW between 14–16% has limited discriminatory value and requires integration with MCV, serum ferritin, JAK2 mutation status, and clinical features (splenomegaly, pruritus, thrombocytosis) to establish the diagnosis 8, 9.

Practical Summary

  • Normal RDW (≤14%) + elevated Hb/Hct → Think PV; order JAK2 and EPO 4.
  • Elevated RDW (>17%) + low MCV + elevated Hb/Hct → Think iron-deficient PV; order JAK2, ferritin, and transferrin saturation 3, 6.
  • Elevated RDW (>17%) + low MCV + normal Hb/Hct + thrombocytosis/leukocytosis → Think masked PV; order JAK2 immediately 3.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[Clinical significance of red cell distribution width in polycythemia vera].

Rinsho byori. The Japanese journal of clinical pathology, 1989

Guideline

Secondary Polycythemia Diagnosis and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Diagnosis of Polycythemia Vera – Role of Erythropoietin and Molecular Testing

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Assessment Protocol for Incidental Erythrocytosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.